Berg Enters CRADA for Prostate Cancer Biomarker Discovery | GenomeWeb

NEW YORK (GenomeWeb News) – Biopharmaceutical firm Berg and the US Department of Defense today announced an agreement to discover biomarkers for prostate cancer and to develop more effective treatments for the disease.

The deal is in the form of a Cooperative Research and Development agreement with the Uniformed Services University of the Health Sciences' Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.